Re-Engineering Clinical Trials: Best Practices for Streamlining the Development Process

0 avg rating
( 0 ratings by GoodReads )
 
9780124202467: Re-Engineering Clinical Trials: Best Practices for Streamlining the Development Process

The pharmaceutical industry is currently operating under a business model that is not sustainable for the future. Given the high costs associated with drug development, there is a vital need to reform this process in order to provide safe and effective drugs while still securing a profit. Re-Engineering Clinical Trials evaluates the trends and challenges associated with the current drug development process and presents solutions that integrate the use of modern communication technologies, innovations and novel enrichment designs. This book focuses on the need to simplify drug development and offers you well-established methodologies and best practices based on real-world experiences from expert authors across industry and academia. Written for all those involved in clinical research, development and clinical trial design, this book provides a unique and valuable resource for streamlining the process, containing costs and increasing drug safety and effectiveness. * Highlights the latest paradigm-shifts and innovation advances in clinical research * Offers easy-to-find best practice sections, lists of current literature and resources for further reading and useful solutions to day-to-day problems in current drug development * Discusses important topics such as safety profiling, data mining, site monitoring, change management, increasing development costs, key performance indicators and much more

"synopsis" may belong to another edition of this title.

About the Author:

Peter Sch ler is Senior Vice President, Global Medical & Safety Services, ICON Plc. Peter is board certified in neurology (1996; German Medical Board) and in Pharmaceutical Medicine (2001; Swiss Medical Association). In 1999 in obtained a Certificate in Business Administration by Henley Management College, UK. After his medical education he started is professional career in 1987 at the Medical Imaging Application Center of Siemens AG Medical Solutions. The same year he started at the Department of Experimental Neuropsychiatry of the Neurological University Hospital Erlangen, Germany. During the coming 8 years he was involved in basic and clinical CNS research. He held the position of Secretary General of the German section of the International League Against Epilepsy (ILAE; 1991-1995) and was awarded two scientific awards (Alfred-Hauptman epilepsy prize and ILAE Young Investigator Award). In 1995 he joined Pharmacia. During that period, he participated in the launch of two NCEs in the indications Parkinson's and major depression. In October 2000 he moved into the CRO business, building a department for Medical Affairs and also taking over responsibilities for clinical operations in Germany, Austria and Switzerland. In 2007, Peter joined ICON, now overseeing over 360 people located in 11 major offices in Argentina, Brazil, Germany, India, Japan, Latvia, Mexico, Poland, Singapore, UK and US. He issued several publications on drug safety and authored an eBook about clinical trial design and conduct (Zenosis Ltd publisher) and continues to lecture Pharmaceutical Medicine at the Universities of Duisburg-Essen, Germany and Aveiro, Portugal. Brendan Buckley is Chief Medical Officer of ICON Plc. He was previously a co-founder of Firecrest Clinical. He is a Honorary Clinical Professor in the School of Medicine at University College Cork Ireland. A medical graduate of the National University of Ireland and a doctoral graduate in Biochemistry of Oxford University, he has over 30 years' experience in clinical pharmacology research. Prior to joining ICON, he was Director of the European collaborative Centre for Clinical Trials in Rare Diseases at Cork. He was a member of the EMA Committee for Orphan Medicinal Products (COMP) from 2000-2003 and a member of the EMA Scientific Advisory Committee on Diabetes and Metabolism until 2011. He was a member of the Board of Directors of the Irish Medicines Board, the national competent authority for Ireland, 2004-2011 and chaired its statutory Advisory Committee for Human Medicines. He is chairman of the independent data and safety monitoring boards for a number of large clinical trials programmes with several sponsors. He is a member of the scientific advisory boards of a number of research charities and honorary Director of the Cork Cancer Research Centre. Professor Buckley is a Fellow of the Royal College of Physicians of Ireland, of the College's Faculty of Pathology and a Fellow of the Faculty of Sports and Exercise Medicine.

About the Author:

Brendan Buckley is Chief Medical Officer of ICON Plc. He was previously a co-founder of Firecrest Clinical. He is a Honorary Clinical Professor in the School of Medicine at University College Cork Ireland. A medical graduate of the National University of Ireland and a doctoral graduate in Biochemistry of Oxford University, he has over 30 years' experience in clinical pharmacology research. Prior to joining ICON, he was Director of the European collaborative Centre for Clinical Trials in Rare Diseases at Cork. He was a member of the EMA Committee for Orphan Medicinal Products (COMP) from 2000-2003 and a member of the EMA Scientific Advisory Committee on Diabetes and Metabolism until 2011. He was a member of the Board of Directors of the Irish Medicines Board, the national competent authority for Ireland, 2004-2011 and chaired its statutory Advisory Committee for Human Medicines. He is chairman of the independent data and safety monitoring boards for a number of large clinical trials programmes with several sponsors. He is a member of the scientific advisory boards of a number of research charities and honorary Director of the Cork Cancer Research Centre. Professor Buckley is a Fellow of the Royal College of Physicians of Ireland, of the College's Faculty of Pathology and a Fellow of the Faculty of Sports and Exercise Medicine. Peter Sch ler is Senior Vice President, Global Medical & Safety Services, ICON Plc. Peter is board certified in neurology (1996; German Medical Board) and in Pharmaceutical Medicine (2001; Swiss Medical Association). In 1999 in obtained a Certificate in Business Administration by Henley Management College, UK. After his medical education he started is professional career in 1987 at the Medical Imaging Application Center of Siemens AG Medical Solutions. The same year he started at the Department of Experimental Neuropsychiatry of the Neurological University Hospital Erlangen, Germany. During the coming 8 years he was involved in basic and clinical CNS research. He held the position of Secretary General of the German section of the International League Against Epilepsy (ILAE; 1991-1995) and was awarded two scientific awards (Alfred-Hauptman epilepsy prize and ILAE Young Investigator Award). In 1995 he joined Pharmacia. During that period, he participated in the launch of two NCEs in the indications Parkinson's and major depression. In October 2000 he moved into the CRO business, building a department for Medical Affairs and also taking over responsibilities for clinical operations in Germany, Austria and Switzerland. In 2007, Peter joined ICON, now overseeing over 360 people located in 11 major offices in Argentina, Brazil, Germany, India, Japan, Latvia, Mexico, Poland, Singapore, UK and US. He issued several publications on drug safety and authored an eBook about clinical trial design and conduct (Zenosis Ltd publisher) and continues to lecture Pharmaceutical Medicine at the Universities of Duisburg-Essen, Germany and Aveiro, Portugal.

"About this title" may belong to another edition of this title.

Top Search Results from the AbeBooks Marketplace

1.

Brendan Buckley
Published by Elsevier Science Publishing Co Inc, United States (2015)
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover Quantity Available: 10
Seller
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description Elsevier Science Publishing Co Inc, United States, 2015. Hardback. Book Condition: New. 230 x 154 mm. Language: English . Brand New Book. The pharmaceutical industry is currently operating under a business model that is not sustainable for the future. Given the high costs associated with drug development, there is a vital need to reform this process in order to provide safe and effective drugs while still securing a profit. Re-Engineering Clinical Trials evaluates the trends and challenges associated with the current drug development process and presents solutions that integrate the use of modern communication technologies, innovations and novel enrichment designs. This book focuses on the need to simplify drug development and offers you well-established methodologies and best practices based on real-world experiences from expert authors across industry and academia. Written for all those involved in clinical research, development and clinical trial design, this book provides a unique and valuable resource for streamlining the process, containing costs and increasing drug safety and effectiveness. * Highlights the latest paradigm-shifts and innovation advances in clinical research * Offers easy-to-find best practice sections, lists of current literature and resources for further reading and useful solutions to day-to-day problems in current drug development * Discusses important topics such as safety profiling, data mining, site monitoring, change management, increasing development costs, key performance indicators and much more. Bookseller Inventory # AA59780124202467

More Information About This Seller | Ask Bookseller a Question

Buy New
49.82
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

2.

Brendan Buckley
Published by Elsevier Science Publishing Co Inc 2014-12-19, San Diego (2014)
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover Quantity Available: 1
Seller
Blackwell's
(Oxford, OX, United Kingdom)
Rating
[?]

Book Description Elsevier Science Publishing Co Inc 2014-12-19, San Diego, 2014. hardback. Book Condition: New. Bookseller Inventory # 9780124202467

More Information About This Seller | Ask Bookseller a Question

Buy New
50.99
Convert Currency

Add to Basket

Shipping: 4.50
From United Kingdom to U.S.A.
Destination, Rates & Speeds

3.

Brendan Buckley
Published by Elsevier Science Publishing Co Inc
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover Quantity Available: 1
Seller
THE SAINT BOOKSTORE
(Southport, United Kingdom)
Rating
[?]

Book Description Elsevier Science Publishing Co Inc. Hardback. Book Condition: new. BRAND NEW, Re-Engineering Clinical Trials: Best Practices for Streamlining the Development Process, Peter Schueler, Brendan Buckley, The pharmaceutical industry is currently operating under a business model that is not sustainable for the future. Given the high costs associated with drug development, there is a vital need to reform this process in order to provide safe and effective drugs while still securing a profit. Re-Engineering Clinical Trials evaluates the trends and challenges associated with the current drug development process and presents solutions that integrate the use of modern communication technologies, innovations and novel enrichment designs. This book focuses on the need to simplify drug development and offers you well-established methodologies and best practices based on real-world experiences from expert authors across industry and academia. Written for all those involved in clinical research, development and clinical trial design, this book provides a unique and valuable resource for streamlining the process, containing costs and increasing drug safety and effectiveness. * Highlights the latest paradigm-shifts and innovation advances in clinical research * Offers easy-to-find best practice sections, lists of current literature and resources for further reading and useful solutions to day-to-day problems in current drug development * Discusses important topics such as safety profiling, data mining, site monitoring, change management, increasing development costs, key performance indicators and much more. Bookseller Inventory # B9780124202467

More Information About This Seller | Ask Bookseller a Question

Buy New
49.69
Convert Currency

Add to Basket

Shipping: 5.94
From United Kingdom to U.S.A.
Destination, Rates & Speeds

4.

Brendan Buckley
Published by Academic Press (2014)
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Quantity Available: 1
Seller
Books2Anywhere
(Fairford, GLOS, United Kingdom)
Rating
[?]

Book Description Academic Press, 2014. HRD. Book Condition: New. New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. Bookseller Inventory # GB-9780124202467

More Information About This Seller | Ask Bookseller a Question

Buy New
47.03
Convert Currency

Add to Basket

Shipping: 9
From United Kingdom to U.S.A.
Destination, Rates & Speeds

5.

Brendan Buckley
Published by Academic Press (2015)
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover Quantity Available: 1
Seller
Book Deals
(Lewiston, NY, U.S.A.)
Rating
[?]

Book Description Academic Press, 2015. Book Condition: New. Brand New, Unread Copy in Perfect Condition. A+ Customer Service!. Bookseller Inventory # ABE_book_new_0124202462

More Information About This Seller | Ask Bookseller a Question

Buy New
58.15
Convert Currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, Rates & Speeds

6.

Brendan Buckley
Published by Elsevier Science Publishing Co Inc, United States (2015)
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover Quantity Available: 10
Seller
The Book Depository US
(London, United Kingdom)
Rating
[?]

Book Description Elsevier Science Publishing Co Inc, United States, 2015. Hardback. Book Condition: New. 230 x 154 mm. Language: English . Brand New Book. The pharmaceutical industry is currently operating under a business model that is not sustainable for the future. Given the high costs associated with drug development, there is a vital need to reform this process in order to provide safe and effective drugs while still securing a profit. Re-Engineering Clinical Trials evaluates the trends and challenges associated with the current drug development process and presents solutions that integrate the use of modern communication technologies, innovations and novel enrichment designs. This book focuses on the need to simplify drug development and offers you well-established methodologies and best practices based on real-world experiences from expert authors across industry and academia. Written for all those involved in clinical research, development and clinical trial design, this book provides a unique and valuable resource for streamlining the process, containing costs and increasing drug safety and effectiveness. * Highlights the latest paradigm-shifts and innovation advances in clinical research * Offers easy-to-find best practice sections, lists of current literature and resources for further reading and useful solutions to day-to-day problems in current drug development * Discusses important topics such as safety profiling, data mining, site monitoring, change management, increasing development costs, key performance indicators and much more. Bookseller Inventory # AA59780124202467

More Information About This Seller | Ask Bookseller a Question

Buy New
58.17
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

7.

Brendan Buckley
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover Quantity Available: 1
Seller
Ria Christie Collections
(Uxbridge, United Kingdom)
Rating
[?]

Book Description Hardback. Book Condition: New. Not Signed; The pharmaceutical industry is currently operating under a business model that is not sustainable for the future. Given the high costs associated with drug development, there is a vital need to reform this process in order to provide safe and effective drugs while still securing a profit. Re-Engine. book. Bookseller Inventory # ria9780124202467_rkm

More Information About This Seller | Ask Bookseller a Question

Buy New
57.88
Convert Currency

Add to Basket

Shipping: 2.85
From United Kingdom to U.S.A.
Destination, Rates & Speeds

8.

Brendan Buckley
Published by Academic Press 1, United States
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover Quantity Available: 1
Seller
Powell's Books
(Portland, OR, U.S.A.)
Rating
[?]

Book Description Academic Press 1, United States. Hardcover. Book Condition: New. HARDCOVER Legendary independent bookstore online since 1994. Reliable customer service and no-hassle return policy. New Arrivals. Book: NEW, New. Bookseller Inventory # 64978012420246700. Bookseller Inventory # 64978012420246700

More Information About This Seller | Ask Bookseller a Question

Buy New
57.26
Convert Currency

Add to Basket

Shipping: 3.57
Within U.S.A.
Destination, Rates & Speeds

9.

Brendan Buckley
Published by Academic Press (2014)
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover Quantity Available: 1
Seller
Green Books
(Wicklow, Ireland)
Rating
[?]

Book Description Academic Press, 2014. Hardcover. Book Condition: New. Brand New Book. Shipping: Once your order has been confirmed and payment received, your order will then be processed. The book will be located by our staff, packaged and despatched to you as quickly as possible. From time to time, items get mislaid en route. If your item fails to arrive, please contact us first. We will endeavour to trace the item for you and where necessary, replace or refund the item. Please do not leave negative feedback without contacting us first. All orders will be dispatched within two working days. If you have any quesions please contact us. Bookseller Inventory # V9780124202467

More Information About This Seller | Ask Bookseller a Question

Buy New
57.88
Convert Currency

Add to Basket

Shipping: 4.22
From Ireland to U.S.A.
Destination, Rates & Speeds

10.

Brendan Buckley
Published by Academic Press (2015)
ISBN 10: 0124202462 ISBN 13: 9780124202467
New Hardcover First Edition Quantity Available: 1
Rating
[?]

Book Description Academic Press, 2015. Book Condition: New. Editor(s): Schueler, Peter; Buckley, Brendan. Num Pages: 360 pages, Illustrated. BIC Classification: MBGR; MMG. Category: (P) Professional & Vocational. Dimension: 160 x 231 x 24. Weight in Grams: 692. . 2015. 1st Edition. Hardcover. . . . . . Bookseller Inventory # V9780124202467

More Information About This Seller | Ask Bookseller a Question

Buy New
63.18
Convert Currency

Add to Basket

Shipping: FREE
From Ireland to U.S.A.
Destination, Rates & Speeds

There are more copies of this book

View all search results for this book